Utilize este identificador para referenciar este registo: http://hdl.handle.net/10400.10/696
Título: Human plasma derived prothrombin complex concentrate (OCTAPLEX), the HFF, EPE: Blood Department experience.
Autor: Barra, A
Barradas, A
Cardoso, E
Costa, C
Gil, A
Rodrigues, T
Silva, A
Simões, A
Venâncio, B
Palavras-chave: Anticoagulantes
Hipoprotrombinemias
Hypoprothrombinemias
Anticoagulants
Data: 2011
Editora: International Society for Blood Transfusion
Citação: REGIONAL CONGRESS OF THE ISBT, Europe, 21, Lisboa, June 18 - 22, 2011
Resumo: Background: The HPDPCC was introduced in our clinical practice in 2005, and it has some specific clinical recommendations . We use Octaplex mostly to recert coagulation parameters in patients whose status require their quick conversion, mainly to reverse oral anticoagulation. We initially started using Octaplex in lower doses than the recommended by the drug leaflet, trying to find an optimal dose, aiming to avoid side effects. Aims: Our goals are to share our experience using Octaplex in clinical practice, demonstrating that we can obtain rapid results with minimal dose, without adverse events. Methods: We only included in this study patients who have done Octaplex (1unit – 20ml) and have results of measurement of their International Normalized Ratio (INR) before and after the infusion of prothrombin complex concentrate. The INR was determined using the fully automated hemostasis analyser BCS XP System (Siemens) and the reagent Innovin (Dade Behring). The period of the study was, 2005-2010, and included 87 patients with different diseases. The INR results upper than 10 were counted like 10 because the laboratory doesn’t quantify values higher than this. Results: The patients were 64 men and 23 women, with ages ranged between 18 and 85-years-old, average 66,5-years-old 53 were under treatment with oral anticoagulants (OAC), 22 with liver impairment (1.1), and 12 with other pathologies (OP). The INR before treatment varied from 10 (maximal value) to 1.4 (minimal value), the average values were 6.72 to the patients under OAC, 2.15 to the patients with LI and 3.39 to the patients with OP. After treatment the average values were 2.0 to the OAC 1.84 to the LI and 1.76 to the OP. After treatment the maximal value of the INR was 6.9 and the minimal 0.9. The average number of units used to revert the patients clinical status were for OAC 1.62 (in an average of 1.4 number of intakes), for LI 2 units (1 intake) and for OP 2.75 units (1.42 intakes). We didn’t find any adverse post-administration events. Summary/Conclusions: We found better results in the administration of Octaplex in patients doing OAC, where the 1.62 units (in 1.04 intakes) lowered the INR average from 6.72 to 2.0. The dose used to resolve our clinical cases were much lower than the recommended in the drug leaflet. We didn’t find any adverse events in this dose. The clinical practice feedback suggests a quicker INR conversion comparing to fresh frozen plasma.
Peer review: yes
URI: http://hdl.handle.net/10400.10/696
Aparece nas colecções:IMU - Comunicações e Conferências

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
Cartaz_Co-infecções_doentes infectados_VHC_população estudada_HPDFF_2o EBMS_2012.pdf404,35 kBAdobe PDFVer/Abrir


FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.